"Pharmaceutical companies are developing these drugs now. They will probably be available for testing from 2012", said Prof Barzilai, speaking at the Royal Society in London for a discussion meeting on the science of aging.
Among the substances being looked at are sirtuins, a family of enzymes associated with a range of age-related diseases including type 2 diabetes & cancers, & another enzyme called cholesterol ester transfer protein which affects levels of "good" cholesterol, or high-density lipoprotein.
GlaxoSmithKline, the UK's biggest pharmaceutical company, Merck & Co & Roche 've launched research & drug development programmes into the drugs, with results expected in the coming years. Smaller companies, such as Massachusetts-based Proteostasis, are investigating other pathways involving the cell-growth chemical insulin-like growth factor-1.
No comments:
Post a Comment